Aminoglycoside bactericidal activity during the first 24 h of treatment probably is a determining parameter in the prognosis of severe gram-negative infections in immunocompromised patients. To identify the predictive factors involved in the definition of the best therapeutic regimen for Enterobacter cloacae and Serratia marcescens infections, we studied different gentamicin, tobramycin, and amikacin regimens by using an experimental model of rabbit endocarditis. Two factors appear to play an important role in predicting in vivo efficacy: (i) the level of in vivo bactericidal activity, which can differ widely from one aminoglycoside to another for the same bacterial strain and from one strain to another of the same species, and (ii) the critical serum drug concentration (CSC, in milligrams per liter), defined as the lowest serum antibiotic concentration capable of producing a significant CFU reduction (P < 0.05) in endocarditis vegetations 24 h after the beginning of a continuous infusion. Stepwise regression analysis showed that for gentamicin and S. marcescens, the area under the concentration-time curve above the CSC and then the time above the CSC are the determining parameters for efficacy (R = 0.69; F = 13.5; P = 0.001), whereas for amikacin and S. marcescens, the time above the CSC and then the area under the concentration-time curve above the CSC predict efficacy (R = 0.74; F = 24.0; P = 0.0001). The lowest CSC is that ofamikacin (about 8 mg/liter); those of gentamicin and tobramycin are about 15 mg/liter. In severe S. marcescens infections, intermittent amikacin dosing offers excellent bactericidal activity within the first 24 h.
It has been seen in numerous clinical and experimental studies that once-daily dosing of an aminoglycoside is at least as effective as administration of the same quantity of drug as divided doses (1, 11, 13) . However, most of these studies examined only a limited number of bacterial species (Escherichia coli, Kebsiellapneumoniae, and Pseudomonas aeruginosa), and all compared the effects of several treatment regimens (including once-daily dosing) with the same aminoglycoside (4, 13) . Among gram-negative bacteria, Enterobacter and Serratia species have assumed increasing importance in the last few years (17, 26) . In one French series, Enterobacter and Serratia species accounted for 21 of 134 (15.6%) cases of gram-negative septicemia recorded in 1989 (2) .
Investigation of the in vivo bactericidal activities of antibiotics in the first 24 h after administration is probably an important measure, with potentially crucial implications for human use, principally in neutropenic (or aplastic) patients.
In a recent experimental study (22) , we showed that the same doses of gentamicin, tobramycin, and amikacin had different effects in a model of Serratia marcescens endocarditis, despite similar pharmacokinetics. In brief, the same single dose administered as an intravenous (i.v.) bolus injection exhibited the best efficacy for gentamicin, whereas the same dose administered as a continuous i.v. infusion exhibited the best efficacy for amikacin. Furthermore, one in vitro study (12) has suggested that higher initial peak concentrations of aminoglycosides are necessary to achieve bactericidal activity for S. marcescens and Enterobacter * Corresponding author.
cloacae, compared with most susceptible species, such as E. coli. Thus, the recommended dosage regimens for aminoglycosides are not necessarily identical from one species to another.
Finally, although many authors (3, 4, 10, 18, 25) have demonstrated a good correlation between some pharmacokinetic parameters and in vivo bactericidal activities of aminoglycosides, these studies usually used an in vitro parameter (usually the MIC) to establish the correlation.
In an attempt to identify, at least in part, the factors affecting in vivo aminoglycoside activity, we chose to study the in vivo effects of gentamicin, tobramycin, and amikacin at various dosage regimens on both E. cloacae and S. marcescens experimental endocarditis. We tried to confirm the importance of the in vitro killing rate in the efficacy of a single i.v. bolus dose, as previously shown in the same model of E. coli endocarditis (23) . The second parameter which was investigated was the critical serum drug concentration (CSC, in milligrams per liter), defined as the lowest serum antibiotic concentration able to achieve significant in vivo bactericidal activity 24 h after the beginning of a continuous i.v. infusion in the S. marcescens endocarditis model. Thus, we expected to explain some of the differences in the results reported in the literature regarding the optimum doses of aminoglycosides (11, 15) log1o CFU/ml. The sensitivity limit of detection was 2.4 log1o CFU/ml (7) . Expression of the results was described in a previous work (9) . In brief, the number of surviving bacteria was expressed as log1o CFU per milliliter after each incubation period (1.5, 3, 5, and 24 h). Only the early phase of the killing curve (i.e., the first S h) was plotted on a graph. For (c) In vivo effect of multiple doses of amikacin on S. marcescens endocarditis. Since the continuous infusion of amikacin over 24 h appeared more effective in the S. marcescens endocarditis model than the same dose administered as a single bolus injection (22) , various split-dose regimens (6 mg/kg every 6 h, 12 mg/kg every 6 h, 12 mg/kg every 12 h, and 24 mg/kg every 12 h) were tested in some animals to verify that a 24-h continuous i.v. infusion was predictive of the efficacy of a split-dose regimen.
(ii) Evaluation of treatment. The effect of each treatment was evaluated 24 h after the therapeutic regimen assigned was begun. The animals were sacrificed with an i.v. bolus injection of thiopental. The heart was removed, and vegetations were excised and rapidly rinsed in sterile saline. Some of the vegetations were weighed and homogenized in a Thomas Teflon pestle tissue homogenizer with 0.5 ml of sterile saline. Serial dilutions of 0.05 ml of the homogenate were spread by use of a Spiral System (Interscience) and quantitatively cultured for 24 h at 37°C on Trypticase soy agar plates containing 3% SPS, avoiding a carryover phenomenon. Bacterial titers were expressed as log1o CFU per gram of vegetation. We were able to detect quantities as small as 20 CFU/ml of homogenate, and the value integrated for the calculation of the mean bacterial titer took into account the weights of vegetations. Part of each vegetation was frozen prior to the antibiotic assays.
(iii) Pharmacokinetic studies. Blood samples were taken from three animals in each group to determine the plasma concentration-time curve for each therapeutic regimen. Animals from the following different bolus groups were studied: 24 mg/kg for gentamicin; 6, 12, 24 , and 72 mg/kg for VOL. 36, 1992 on August 14, 2017 by guest http://aac.asm.org/ Downloaded from amikacin; and 72 mg/kg for tobramycin. For the continuous infusion groups, blood samples were taken after 6 h (steady state) from animals receiving 24 mg of amikacin per kg or 72 mg of tobramycin or gentamicin per kg.
The blood samples were obtained by placement under local anesthesia of a catheter in the left femoral artery in rabbits receiving a bolus injection and by acute femoral puncture in animals receiving a continuous infusion. The samples were immediately centrifuged, and the serum was frozen until the time of the assays.
The various pharmacokinetic parameters (half-life, total AUC, time or AUC above the CSC, and MIC) were calculated by use of a monocompartmental model with the aid of our own computer program.
(iv) Antibiotic assays. Serum antibiotic concentrations for each antibiotic regimen were determined by use of a microbiological assay with Bacillus subtilis ATCC 6633. The range of measurable concentrations with this strain was 0.06 to 1 ,ug/ml for all three antibiotics.
After being weighed and homogenized with 0.3 ml of 0.1 M phosphate buffer, the vegetations were centrifuged and the supernatant fluid was sampled for a microbiological assay. The same strain of B. subtilis as that listed above was used.
(v) Statistical evaluation. MBCs) for the S. marcescens strain studied were 0.5 ,g of gentamicin per ml and 1 ,ug of tobramycin or amikacin per ml. The MICs (and MBCs) for both of the E. cloacae strains studied were 0.5 ,ug of gentamicin or tobramycin per ml and 1 ,ug of amikacin per ml.
(ii) Killing curves. The 5-h bacterial killing curves obtained after exposure of the S. marcescens strain to the three aminoglycosides are shown in Fig. 1 for each concentration studied. Each concentration at which the ISB was greater than 100% corresponds to regrowth. At all concentrations above 1 ,ug/ml, the percentage of surviving bacteria at 5 h (expressed as the ISB) was consistently lower for gentamicin than for amikacin or tobramycin. Figure 2 shows the differences observed with tobramycin and gentamicin for the two strains of E. cloacae, strain E475 being killed more rapidly than strain E474 at concentrations between 2 and 32 ,ug/ml. These results represent the mean of three consecutive experiments. The differences observed were far above the standard deviation of the method of iSB (XAUC) counting (see Materials and Methods) and appeared highly significant.
In each experiment, it was possible to confirm that the MICs for the surviving bacteria were the same as those for the parental strain with respect to the tested antibiotics. For E. cloacae endocarditis, the same bolus dose of gentamicin or tobramycin (48 mg/kg) produced a significant reduction in the CFU of strain E475 but not strain E474 (Table 1) .
For S. marcescens endocarditis, we showed in an earlier study (22) Fig. 1 ). 24 h, a number of animals were sacrificed 6 h after the same dose was administered as a bolus injection to evaluate in vivo bacterial killing by this antibiotic. Bactericidal activity was already very marked 6 h after a dose of 48 mg/kg (3.5 ± 1.9 log1o CFU/g of vegetation; P = 0.003), whereas it was not significant after a dose of 24 mg/kg (5.1 ± 2.5 log1o CFU/g of vegetation).
(ii) Determination of the CSC for the S. marcescens strain. The results obtained for determination of the CSC for the S. marcescens strain at the various concentrations studied are shown in Table 2 12 h) , the AUC was calculated from 0 to 6 h (or 12 h) and then multiplied by 4 (or 2) to obtain the AUC over 24 h. P = 0.03). Stepwise regression analysis revealed that the best correlation was shown by AUC above the CSC and then time above the CSC for gentamicin (R = 0.69; F = 13.54; P = 0.001), compared with time above the CSC and then AUC above the CSC for amikacin (R = 0.74; F = 24.07; P = 0.0001).
DISCUSSION
The mode of administration of aminoglycosides has been a subject of debate for many years. A number of clinical studies in the late 1970s (8, 14) encouraged the use of continuous infusion in combination with a beta-lactam antibiotic for neutropenic patients. However, these studies were not comparative. Nevertheless, in the study of Keating et al. (14) , the combination of carbenicillin and amikacin as a continuous infusion proved more effective than that of carbenicillin and gentamicin as a continuous infusion for the treatment of septicemia in neutropenic patients, although it was not possible to establish the respective roles of the aminoglycoside concentrations or that gram-negative bacilli are less susceptible to gentamicin (in terms of the MIC). Our results seem to show that the in vivo activities of aminoglycosides (and the best dosage schedules) depend on many factors, including the bacterial species, the strain studied, the aminoglycoside used, and probably the site of infection.
To identify the factors predictive of the best dosage regimen for a severe gram-negative intravascular infection, we determined in vitro (killing rate) and in vivo (CSC) parameters to explain the differences in the in vivo activities of three aminoglycosides.
In the E. cloacae endocarditis model, despite the similar MICs of the two compounds used (gentamicin and tobramycin), the slight difference in the in vivo activity of a single i.v. bolus injection (48 mg/kg) on the two strains (E474 and E475) could have been related to the higher killing rate in vitro (expressed as the ISB) of these two drugs for strain E475 than for strain E474. This result is in agreement with that of a previous study (23) , in which a good correlation was demonstrated between the in vitro killing rate and the in vivo effect of a single dose of antibiotic in an E. coli endocarditis model. Similarly, the better in vitro activity of gentamicin than of tobramycin or amikacin on the strain of S. marcescens was probably responsible for the low MED of the former compound (48 mg/kg for gentamicin versus 72 mg/kg for amikacin and tobramycin). Nevertheless, determination of the CSC seemed to be necessaxy to establish a valuable in vivo dose-effect relationship, allowing recommendation of the best dosage regimen for an aminoglycoside in a given bacteriological and clinical situation. In fact, as has been reported in several studies of thigh infection in neutropenic mice by Craig and colleagues (3, 16, 25) , time above the MIC is most often the best predictor of the in vivo efficacies of aminoglycosides for the majority of tested strains, as long as the dosage interval is over 6 h. Under these conditions, in which the administered substance is rapidly eliminated by small animals, high, extremely bactericidal aminoglycoside concentrations cannot be maintained for a sufficient time to produce an in vivo bactericidal effect. In our study, AUC above the CSC was still important for the three antibiotics tested but was more important for gentamicin than for amikacin. The fact that gentamicin had the lowest MED (48 mg/kg) for S. marcescens is explained by the much higher bacterial killing rate with this drug than with amikacin or tobramycin. Sacrifice of the animals treated with gentamicin after 6 h confirmed that most of the bactericidal activity took place in the first 6 h, during which concentrations in excess of the CSC were observed in the serum for about 3 h. In the case of amikacin, the same dose of antibiotic resulted in no bactericidal activity at the end of 24 h since, although the concentrations in serum exceeded the CSC for 6 h, this period was inadequate to allow the expression of a bactericidal effect slower than that of gentamicin. The results for the multiple doses of amikacin were in agreement with those obtained by Craig et al. for mice with S. marcescens thigh infections (4) . The cumulative 24-h dose required to achieve a bactericidal effect in vivo increased with the length of the dosage intervals (24, 48 , and 72 mg/kg for intervals of 6, 12, and 24 h, respectively). It should be noted that a possible postantibiotic effect was not investigated in our model, since the residual concentrations in the vegetations were always equal or superior to the MIC, thus excluding the possibility of regrowth as well.
Studies comparing the relative efficacies of several aminoglycosides in the same model of gram-negative infection are rare, while experimental or clinical studies comparing the efficacy of a once-daily injection with that of intermittent dosing yield divergent results (1, 13, 20, 24, 25) . One of the reasons for these differences could be a failure to take into account the in vitro bacterial killing rate, which seemed to play a major predictive role in the present study for (6) . Thus, a possible conclusion that can be extrapolated to humans with severe S. marcescens infections is that amikacin, administered as three or four daily doses or as a continuous infusion, displays outstanding efficacy within 24 h of administration. Shorter intervals are probably not suitable, because of the possibility of a down-regulation phenomenon, responsible for adaptive resistance in the 6 h following a brief exposure to an aminoglycoside (5) .
In conclusion, two factors affect the in vivo efficacies of the aminoglycosides and probably explain, at least in part, the discrepancies reported in the literature for the optimal dosing regimens of these drugs: the in vitro killing rate, which may be measured at several concentrations, and the in vivo CSC, which can be much higher than the MIC. Further studies are needed to examine whether there is a relationship between these early bactericidal effects and the ultimate treatment outcome of severe gram-negative sepsis.
